Polomar Health Services, Inc.
0.2000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · PMHS · USD
Key Stats
Market Cap
5.60MP/E (TTM)
-Basic EPS (TTM)
-0.08Dividend Yield
0%Recent Filings
8-K
Merger amendment details
Polomar Health Services amended its July 23, 2025 merger agreement with Altanine Inc. on October 8, 2025, setting a one-for-one exchange of common stock shares and five preferred shares for each Altanine preferred share, subject to adjustment. This tweak refines the deal structure amid ongoing integration. No financial terms disclosed. Deal advances steadily.
8-K
Amended exclusivity deal signed
Polomar Health Services executed an Amended and Restated Product Fulfillment and Distribution Agreement on August 25, 2025, effective August 19, granting ForHumanity exclusive U.S. marketing rights for its patent-pending inhalable sildenafil and eletriptan through March 31, 2026, in exchange for guaranteed payments totaling $750,000—$200,000 already received—with potential extensions tied to revenue milestones up to $20 million by 2027. The 42-month deal, running to September 16, 2028, positions Polomar to fulfill prescriptions via its specialty pharmacy while IG4 handles account management, aiming to boost sales through ForHumanity's telemedicine network. Exclusivity hinges on hitting targets. Patent approval remains uncertain.
10-Q
Q2 FY2025 results
Polomar Health Services posted Q2 revenue of $5,470, down sharply from $14,495 a year earlier, while six-month totals slid to $10,011 from $28,105, reflecting the post-merger shift to an online model. Gross profit shrank to $3,832 from $10,256, but operating expenses ballooned 182% to $567,165, driven by legal fees, amortization, payroll, and $109,231 in stock-based compensation, yielding an operating loss of $563,333 versus $190,742 last year. Net loss widened to $605,563, or $0.02 per diluted share on 27,667,155 shares, with the extra $42,230 hit from interest expense. Cash dwindled to $4,678 amid $233,357 in operating outflows, offset by $231,844 from related-party notes; related-party debt stood at $597,550, maturing July 2027 at 12%. The September 2024 Polomar merger, a reverse recapitalization, integrated pharmacy operations without disclosed goodwill. Revenue remains vulnerable to regulatory hurdles in expanding state licenses.
8-K
Polomar-Altanine merger announced
Polomar Health Services entered a merger agreement on July 23, 2025, with Altanine, where a subsidiary merges into Altanine, making it a wholly owned unit; Altanine shareholders will claim about 80% of Polomar's common stock post-deal, while current Polomar holders retain 20%. The board shifts to four Altanine picks, including new CEO Charles Andres, Jr., replacing interim chief Terrence Tierney, who moves to EVP. Closing hinges on supermajority stockholder approval, SEC filings, Nasdaq listing, and a reverse split for $10/share pricing. Risks loom if integration falters or conditions fail.
8-K
Affiliate loan secures funding
Polomar Health Services inked a promissory note with affiliate CWR 1, LLC on July 21, 2025, securing up to $150,000 in funding at 12% interest, maturing October 31, 2025. It snagged an initial $60,000 draw tied to a merger agreement with Altanine, Inc., while further advances hinge on milestones like stock exchange listing. This bridges cash needs amid integration risks, yet default could spike rates to prime plus 7%. Short-term liquidity boost.
BLMH
Blum Holdings Inc.
0.65+0.00
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.39+0.00
CPMD
Cannapharmarx Inc.
0.01+0.00
HIMS
Hims & Hers Health, Inc.
46.63-0.49
MGRX
Mangoceuticals, Inc.
2.18+0.11
PETS
PetMed Express, Inc.
2.59+0.02
PLMR
Palomar Holdings, Inc.
112.49-0.27
PNPL
Pineapple, Inc.
0.12+0.00
SRXH
SRX Health Solutions, Inc.
0.34-0.03
WGRX
Wellgistics Health, Inc.
0.62-0.03